Friday, 22 September 2023

Business News

Taysha Gene Therapies (TSHA) Receives a Buy from Chardan Capital – TipRanks Financial Blog

LianBio reports Q3 EPS (20c), consensus (39c)

In a report released yesterday, Geulah Livshits from Chardan Capital reiterated a Buy rating on Taysha Gene Therapies (TSHAResearch Report), with a price target of $4.00. The company’s shares closed yesterday at $3.26.

According to TipRanks, Livshits is a 5-star analyst with an average return of 29.9% and a 41.42% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Taysha Gene Therapies, and 4D Molecular Therapeutics.

Currently, the analyst consensus on Taysha Gene Therapies is a Strong Buy with an average price target of $5.83, implying a 78.83% upside from current levels. In a report released yesterday, Truist Financial also maintained a Buy rating on the stock with a $5.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

TSHA market cap is currently $199.8M and has a P/E ratio of -1.35.

Based on the recent corporate insider activity of 14 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TSHA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.

Read More on TSHA:

Click Here to Read the Full Original Article at TipRanks Financial Blog…